KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Gains from Investment Securities (2019 - 2025)

GoodRx Holdings' Gains from Investment Securities history spans 7 years, with the latest figure at -$6.6 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 130.36% year-over-year to -$6.6 million; the TTM value through Dec 2025 reached $15.1 million, down 44.7%, while the annual FY2025 figure was $2.5 million, 89.42% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$6.6 million at GoodRx Holdings, down from $21.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $21.7 million in Q4 2024 and bottomed at -$18.1 million in Q4 2021.
  • The 5-year median for Gains from Investment Securities is $364000.0 (2022), against an average of $3.3 million.
  • The largest annual shift saw Gains from Investment Securities crashed 1087.19% in 2021 before it soared 5137.17% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$18.1 million in 2021, then surged by 131.12% to $5.6 million in 2022, then tumbled by 88.18% to $666000.0 in 2023, then skyrocketed by 3162.61% to $21.7 million in 2024, then tumbled by 130.36% to -$6.6 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Gains from Investment Securities are -$6.6 million (Q4 2025), $21.7 million (Q4 2024), and $666000.0 (Q1 2023).